Compare UNFI & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UNFI | DVAX |
|---|---|---|
| Founded | 1976 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 1996 | 2004 |
| Metric | UNFI | DVAX |
|---|---|---|
| Price | $34.30 | $15.67 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 8 | 5 |
| Target Price | ★ $37.13 | $26.50 |
| AVG Volume (30 Days) | 896.5K | ★ 5.7M |
| Earning Date | 03-10-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,753,000,000.00 | $330,514,000.00 |
| Revenue This Year | $2.45 | $24.63 |
| Revenue Next Year | $2.14 | $15.85 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 1.45 | ★ 26.73 |
| 52 Week Low | $20.78 | $9.20 |
| 52 Week High | $43.29 | $15.73 |
| Indicator | UNFI | DVAX |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 85.69 |
| Support Level | $32.06 | $15.57 |
| Resistance Level | $35.25 | $15.69 |
| Average True Range (ATR) | 1.20 | 0.07 |
| MACD | 0.21 | -0.09 |
| Stochastic Oscillator | 70.53 | 83.33 |
United Natural Foods Inc is a wholesale distributor of natural, organic and specialty foods and nonfood products across North America. The company's products consist of national, regional and private label brands grouped into grocery and general merchandise, produce, perishables and frozen foods, nutritional supplements and sports nutrition, bulk and foodservice products, and personal care items. United Natural Foods serves various retail formats including conventional supermarket chains, natural product superstores, independent retail operators and foodservice channels such as e-commerce platforms. The company's operations are comprised of principal divisions: the wholesale division; the retail division; and other.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.